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Animal models of epilepsyEpilepsy modeling is essential for understanding the basic mechanisms of the epileptic process. The Genetic
Audiogenic Seizure Hamster (GASH:Sal) exhibits generalized tonic–clonic seizures of genetic origin in response
to sound stimulation and is currently being validated as a reliablemodel of epilepsy. Here, we performed a phar-
macological andneuroethological study usingwell-knownandwidely used antiepileptic drugs (AEDs), including
phenobarbital (PB), valproic acid (VPA), and levetiracetam (LEV). The intraperitoneal administration of PB
(5–20 mg/kg) and VPA (100–300 mg/kg) produced a dose-dependent decrease in GASH:Sal audiogenic seizure
severity scores. The administration of LEV (30–100 mg/kg) did not produce a clear effect. Phenobarbital showed
a short plasmatic life and had a high antiepileptic effect starting at 10 mg/kg that was accompanied by ataxia.
Valproic acid acted only at high concentrations and was the AED with the most ataxic effects. Levetiracetam at
all doses also produced sedation and ataxia side effects. We conclude that the GASH:Sal is a reliable genetic
model of epilepsy suitable to evaluate AEDs.
© 2013 Elsevier Inc. All rights reserved.1. Introduction
According to the International League Against Epilepsy (ILAE), epi-
lepsy is deﬁned as a disorder of the brain that is characterized by an
enduring predisposition to epileptic seizures, which are deﬁned as a
transient occurrence of signs and/or symptoms due to abnormal exces-
sive or synchronous neuronal activity in the brain [1,2]. Epilepsy is a dis-
order that has semiologic and genetic heterogeneity because it consists
of a variety of syndromes andmanifestations. Genetic factors are largely
considered to determine the susceptibility to seizure induction and the
neuropathological consequences of epilepsy [3,4]. To our knowledge,
the occurrence of ictogenesis and epileptogenesis is due to a molecular
imbalance generated in the brain between GABA and glutamate, in
addition to other neurotransmitters [5,6], that induces modiﬁcations
in gene transcription, protein expression, and/or the structure of recep-
tors [4,7–10].
Epilepsy modeling is essential for understanding the basic mecha-
nisms of the disease [3,4] and for testing new antiepileptic drugs
(AEDs). Currently, there are a variety of animal models of epilepsy, pri-
marily rodent, and ﬂy, ﬁsh, and worm models [11–13].airasco), sanchoc@usal.es
rights reserved.Genetic Audiogenic Seizure Hamsters (GASH:Sal) are a line of
Syrian golden hamsters (Mesocricetus auratus) that are being validated
as a model of epilepsy. They exhibit acute audiogenic seizures (AS) of
genetic origin in response to sound stimulation. These AS require
the activation of brainstem auditory pathways and originate largely at
the level of the inferior colliculus [14,15]. These hamsters exhibit mor-
phological and neurochemical abnormalities in the auditory pathway
[13,16].
Neuroethology is a useful tool for studying epilepsy, as it analyzes
seizures in an integrated manner using the principle that evaluation of
behavioral sequences is more consistent than studies of isolated behav-
iors [17,18]. Neuroethological studies have been performed in epilepsy
models, such as AS in rats [19], in models that use pilocarpine [20,21],
and in synapsin knockout mice [22]. Further studies have been per-
formed in patientswith temporal lobe epilepsy [23,24]. Associations be-
tween pairs of behaviors in a time frame are used to detect frequency,
duration, and correlation parameters by statistical association. Groups
of behaviors with signiﬁcant associations are conﬁgured as behavioral
clusters [17,18].
As a part of the validation process of the GASH:Sal strain, we
performed the current study using well-known and widely pre-
scribed AEDs, including phenobarbital (PB), valproic acid (VPA), and
levetiracetam (LEV). The goal of this study was to characterize the
pharmacology of these AEDs using neuroethological tools in GASH:
Sal hamsters.
Fig. 1. Flowcharts illustrating the graphical and statistical aspects of the observed behaviors. The frequency and time spent performing each behavior are proportional to the height
and width of the rectangle, respectively. The arrow width and direction indicate the statistical intensity and preference association between two items.
Table 3
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2.1. Animals
Two-month-old male GASH:Sal hamsters were used. They were
obtained from the inbred strain maintained at the animal facility ofTable 1
Seizure index (SI), according to Garcia-Cairasco et al. [18] using the behavioral descrip-
tions and categorized severity index (cSI) transformed into discreet variables for statis-
tical purposes.
Taken from Rossetti et al. [33].
SI Seizure behaviors cSI
0.00 No seizures 0
0.11 One wild running 1
0.23 One wild running (running plus jumping plus atonic fall) 2
0.38 Two wild runnings 3
0.61 Tonic convulsion (opisthotonus) 4
0.85 Tonic seizures plus generalized clonic convulsions 5
0.90 Head ventral ﬂexion plus cSI5 6
0.95 Forelimb extension plus cSI6a 7
1.00 Hind limb extension plus cSI6a 8
a Categories, which are generally followed by hind limb clonic convulsions (CCV2).
Table 2
Ataxia index (AI) scores according to Lösher and Hönack [34].
Taken from Rosetti et al. [33].
Score Behaviors
1 Slight ataxia in hind leg (tottering of hind quarters), no decrease
in abdominal muscle tone
2 More pronounced ataxia with dragging of hind legs and slight
decrease of muscle tone
3 Further increase in ataxia and more pronounced dragging of hind
legs and decrease in muscle tone
4 Marked ataxia, animals lose balance during forward locomotion,
total loss of abdominal muscle tone
5 Very marked ataxia with frequent loss of balance during locomotion,
loss of abdominal muscle tonethe University of Salamanca (USAL, Spain) and were housed during
the experiments in the animal house at the Institute of Neuroscience
of Castilla y León (INCyL) of the USAL. The experimental animals wereSedation index (SdI) scores according to Lösher and Hönack [34].
Taken from Rosetti et al. [33].
Score Behaviors
1 Slightly reduced forward locomotion
2 Reduced locomotion with rest periods in between (partly with closed eyes)
3 Reduced locomotion with more frequent rest periods
4 No forward locomotion; animal sits quietly with closed eyes
Table 4
Behavioral dictionary.
Acronym Behavior Acronym Behavior
AF Atonic fall GRH Grooming of head
ATFa Ataxic fall GRHL Grooming of head, left
BE Blinking eyes GRL Grooming of body, left
BRL Barrel rolling, left GRN Grooming of neck
BRR Barrel rolling, right GRR Grooming of body, right
CCV1 Clonic convulsions (forelegs) HFL Head ventral ﬂexion
CCV2 Clonic convulsions (hind legs) HP1 Forelimb extensions
CCVg Clonic convulsions (generalized) HP2 Hind limb extensions
CVL1 Clonic convulsions (forelegs — left) IM Immobility
CVL2 Clonic convulsions (hind legs— left) JP Jumping
DYS Dyspnea LI Licking
ER Erect posture LIC Licking of claws
EXC Excretion of feces and urine MT Masticatory movements
EXT Extended posture PIM Postictal immobility
FR Freezing posture RU Running
GL Gyrating, left SC Scanning
GN Gnawing SN Snifﬁng
GR Gyrating, right TCP Tachypnea
GRB Grooming WA Walking
GRF Grooming of face WDS Wet dog shaking
GRG Grooming of genitals
a Observation: The behavioral item ataxic fall (ATF) was created to show the presence
of the toxic effect of drugs on motor behavior.
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1201/05) and European (2010/63/EU) Directives under the supervi-
sion of the corresponding Institutional Animal Care and Use Commit-
tee. All efforts were made to avoid unnecessary animal suffering and
to reduce the number of animals used in the study.2.2. Acoustic stimuli
The stimuli were applied in a cylindrical acrylic arena (height:
50 cm; diameter: 37 cm), recorded using a high-pass ﬁlter (>500 Hz;
microphone Bruel & Kjaer #4134 and preampliﬁer Bruel & Kjaer
#2619), digitized above 4 kHz, and reproduced by a computer coupled
to an ampliﬁer (FONESTAR MA-25T, Revilla de Camargo, Spain) and a
tweeter (Beyma T2010, Valencia, Spain) in the upper portion of the
arena. The ﬁnal sound was a semirandom sound of 0–18 kHz with an
intensity of 115 to 120 dB.
The sound of shaking keys can be downloaded from: bhttp://www-
incyl.usal.es//components/com_gestionusuarios/proyectos/audigenic-
sound.mp3>.2.3. AEDs
Three AEDs were used for these experiments: PB (Luminal®, Kern
Pharma), VPA (Depakine®, Sanoﬁ Aventis), and LEV (Kepra®, UCB
Pharma).Fig. 2. Serum concentration levels at various extraction times following the intraperitoneal injec
point is the mean (±S.E.M.) of 5 animals.2.4. Pharmacology of the AEDs
2.4.1. Blood extraction and sample preparation
Blood was extracted at various times postinjection of the AEDs:
30, 60, 120, 240, and 360 min in the case of VPA and LEV and 5, 15,
20, 25, and 30 min in the case of PB. The doses of the drugs were as
follows: 20 mg/kg of PB, 500 mg/kg of VPA, and 100 mg/kg of LEV.
The blood was extracted from the cranial vena cava according to the
procedure described by Picazo et al. [25] under inhalation anesthesia
(induction: 4% isoﬂurane and 1 l/min O2; maintenance: 3% isoﬂurane
and 0.4 l/min O2). At each time point, 100 μl of blood was extracted,
and the animals were rehydrated with 150 μl of 0.9% saline. The sam-
ples were kept at 4 °C until a clot formed and were then centrifuged
for 5 min at 10,000 g at 4 °C. The supernatant (serum) was collected
in 20 μl aliquots and frozen until used. Then, 20 μl of acetonitrile
(Panreac, Barcelona, Spain) and an internal standard (IS)were vortexed
with the serum aliquot, agitated for 5 min, then centrifuged for 5 min at
11,000 g. The supernatant was placed in another tube and left to dry at
room temperature. The samplewas suspended in 20 μl of 20%methanol
in dH2O. The ISs used were as follows: 25 μg/ml acetanilide (Merck,
Darmstadt, Germany) for PB, 20 μg/ml octanoic acid (Panreac) for VPA,
and 20 μg/ml caffeine (LiChro test standard, Merck, Darmstadt,
Germany) for LEV.
2.4.2. Blood drug concentration
Serum level determinationswere carried out to adjust the timing in-
terval for each AED. The blood drug concentrations were determinedtion of the AEDs: (A) PB (10 mg/kg), (B) VPA (500 mg/kg), and (C) LEV (100 mg/kg). Each
416 B. Barrera-Bailón et al. / Epilepsy & Behavior 28 (2013) 413–425using HPLC/MS at the Mass Spectrometry Service of the USAL. The
equipment used for analysis of the samples included an Agilent 1100
(Agilent Technologies, Santa Clara CA, USA) for the HPLC assay and an
Agilent trap XCT (Agilent Technologies) for the mass spectrophotome-
try assay. The mobile phase consisted of A (water containing 0.1%
formic acid) and B (acetonitrile). The mobile phase was delivered at a
ﬂow rate of 0.2 ml/min to a X-Bridge C-18 column (particle size:
3.5 μm; diameter: 2.1 mm; length: 10 cm) (Waters Corporation,
Milford MA, USA). Different methods of elution were used for each
drug [26]. The PB method consisted of a 20% constant rate of the B
phase, and the total run time was 15 min [27,28]. The VPA method
was initiated with 6 min of 40% B phase, which was linearly increased
to 100% B phase over 1 min and was maintained at this concentrationFig. 3. Percentage of animals that exhibited wild running (top) and tonic–clonic convulsion
lacking seizures at the different doses (n = 6). PB (5, 10, 15, and 20 mg/kg), VPA (100, 15for 4 min [29]. The LEV method was initiated with 5% B phase, which
was linearly increased to 20% B phase from 3 to 8 min and was then
maintained at this concentration for 2 min [30].
2.5. Anticonvulsant drug potency: AED doses and acute treatment
The dose of each AEDwas chosen based on its efﬁcacy at suppress-
ing seizures in other experimental models of epilepsy [27,28,30,31].
The administered doses of each drug were as follows: PB — 5, 10,
15, and 20 mg/kg; VPA — 100, 150, 300, and 500 mg/kg; and LEV —
30, 50, 80, and 100 mg/kg. Each animal received different doses
of the same AED 15 to 30 min before the stimuli. In the ﬁrst week,
the animals received the vehicle (0.9% saline; 0.001 ml/g of animals (middle) under the effects of the AEDs. Observe the percentage of animals (bottom)
0, 300, and 500 mg/kg), and LEV (30, 50, 80, and 100 mg/kg).
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one dose per week for a total of ﬁve weeks. A fourth group of animals
was added as a control and received saline instead of drug for all ﬁve
stimuli. Drug potency comparisons were based on administered
dosages and were determined at the individual time of the peak anti-
convulsant effect. The median effective dose (ED50) values for the
various treatment outcomes were calculated following the method
of Litchﬁeld and Wilcoxon [32] in PSS PASW Statistical 18 (IBM).
2.6. Neuroethological study
2.6.1. Behavioral observation
The protocols consisted of three phases of behavioral observation:
1 min of presound, 30 s of sound, and 3 min of postsound. All obser-
vation windows were recorded for further analysis (Fig. 1).
2.6.2. Seizure severity indexes and neuroethological analysis
Three behavioral evaluationswere used. The severity index (Table 1)
was used to determine the intensity of the seizures [17,18,33]. The
ataxia (Table 2) and sedation (Table 3) indexes were used to measure
the toxic effects of the drugs on normal behavior [33,34].
After each animal was scored using the cSI, we divided the animals
into two groups for further analysis. Those with a cSI greater than or
equal to 2 (SI = 0.23) were considered as animals that maintained
seizures, and thosewith a cSI lower than 2were considered as animals
in which the seizures were blocked. The behavioral sequences ob-
served during the different stimuli were assessed using neuroetho-
logical methods. Every behavior presented in a given time window
was recorded, second by second, according to a dictionary of behavior-
al items (Table 4) described by Garcia-Cairasco et al. [18]. Once the
data were obtained, the ETHOMATIC [17,18] program was used for
statistical analysis of the data. This program displays themean frequen-
cy and themean duration of each behavioral item in the given observa-
tion window. The program also performs statistical analysis, verifying
signiﬁcant associations between pairs of behavioral items and calculat-
ing X2 values. Flowcharts representing all of the statistically signiﬁcant
data were constructed using Microsoft Power Point 2011 (see Fig. 1
for ﬂowchart calibration).Fig. 4. Characteristic ﬂowchart of the behavioral sequences of the ﬁrst seizure with no A
(C) postsound window. See behavioral descriptions in Table 4.2.6.3. Statistical analysis
All the statistical analyses were performed using SPSS PASW Statis-
tical 18 (IBM) software. For comparisons between the different AED
doses, we used the nonparametric Friedman test with Conover post
hoc comparisons [35].
3. Results
3.1. Pharmacology of the AEDs in GASH:Sal hamsters
3.1.1. Serum levels
To determine the timing of the maximal levels of the drugs, we
measured blood levels after the intraperitoneal administration of an
effective anticonvulsant dose. The results obtained from the serum
AED concentration analysis (Fig. 2) showed that the blood absorption
and elimination of free PB in GASH:Sal hamsters are excessively fast,
as nondetectable levels of the drugwere recorded 30 min postinjection.
Valproic acid and levetiracetam showed a similar kinetic proﬁle,
reaching the highest serum levels at 30 min postinjection but had a
low but still detectable drug blood concentration after 6 h.
3.1.2. Anticonvulsant effects
The three drugs had anticonvulsant effects at their peak plasma con-
centrations, i.e., 10 min (PB) or 30 min (VPA and LEV) after the i.p. in-
jections (Fig. 2). At low doses, AEDs modiﬁed the seizures (Fig. 3) by
prolonging the time of wild running, by suppressing the tonic–clonic
phase, and by elongating the time of the postictal period. In the case
of PB and VPA, the seizures completely vanished at higher doses.
The anticonvulsant effect of PB was present at the smallest dose
(5 mg/kg), at which approximately 33% of the animals did not present
any of the components of an epileptic seizure. Valproic acid had a 75%
protective effect against seizures at 300-mg/kg dose. Phenobarbital
and valproic acid generated anticonvulsant effects in accordance with
increasing doses. Levetiracetam did not have a dose-dependent anti-
convulsant effect nor did it reach a maximum effect at any of the
doses used. In fact, LEV achieved stronger protective effects (50–66%)
at lower doses (30–50 mg/kg). Levetiracetam did not alter, or only
very slightly altered, wild running at any of the doses used.EDs in GASH:Sal hamsters (n = 24). (A) Presound window, (B) sound window, and
Fig. 5. Flowchart of the sequences of behaviors of the GASH:Sal hamsters injected with different doses of PB.
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Fig. 6. Box plots with A) the categorized seizure severity index (cSI) and B) the ataxic
index (AI) at the different doses of phenobarbital (PB).
419B. Barrera-Bailón et al. / Epilepsy & Behavior 28 (2013) 413–425All three drugs were evaluated for anticonvulsant potency as mea-
sured by the ED50, the dose that completely blocks seizures in 50% of an-
imals after stimulation. The dose of PB that produced 50% seizure
blockade was 10 mg/kg. In the case of VPA, the calculated ED50 was
225 mg/kg. Levetiracetam did not present a linear correlation between
the decrease in seizures related to dose, but the ED50 range was be-
tween 30 and 50 mg/kg.
3.2. Neuroethological study
3.2.1. Characterization of seizures in the GASH:Sal hamster
The seizures of the GASH:Sal hamster, as described by Muñoz and
López [36], consist of generalized tonic–clonic seizures that can be divid-
ed into different phases, starting with (a) a behavioral arrest, followed
by (b) a period of wild running, then (c) tonic–clonic convulsions,
with (d) head ventral ﬂexion, forelimb extension, and hind limb exten-
sion, and ending with (e) postictal immobility. The duration of the con-
vulsive phases is 25.82 ± 2.44 s.
The representative ﬂowcharts of an acute (ﬁrst) seizure in the
GASH:Sal hamster are shown below in more detail (Fig. 4). During the
presound window, the behavioral exploration cluster represents the
main activity of the hamsters. Although the animals did not have
immobility periods, some isolated grooming behaviors were observed.
During the sound window, wild running began approximately 7 s
poststimulus. The third window began with a tonic seizure (TCV),
followed by a behavioral cluster of generalized clonic seizures with hy-
perextensions (HP1 and HP2) and ended with postictal immobility
(PIM).
3.2.2. Characterization of the anticonvulsant effects of AEDs in the GASH:
Sal hamster
At a dose of 5-mg/kg PB, 33.3% of the animals did not have seizures
when stimulated. Animals treated with PB had reduced frequencies of
the exploratory items and had a reduced number of interactions be-
tween the different behaviors involved in this cluster (Fig. 5). During
the stimulus window, the animals maintained some of the wild run-
ning behavioral components, but there were no interactions between
the components, and the animals presented exploratory behavior for
the remainder of the duration of the stimulus. During the last period,
the animals maintained this exploratory behavior at a level lower
than that of control animals. The animals that suffered a seizure at
this dose differ from the control animals in the short presence of ex-
ploratory behaviors and in the convulsive cluster without hind limb
extension. At 10 mg/kg of PB, the animals with no seizure (66.6%)
had an increased frequency of exploratory behavior in all three win-
dows, with the presence of drug-related ataxic falling (ATF; orange
symbol) in the prestimulus window. These animals maintained some
wild running but had no interactions between the components. Some
grooming behaviors appeared during the poststimulus observation
window. The seizures of the drug-treated animals differed from those
of the control animals by a reduction in the interactions of all of the as-
sociated behaviors.
Orofacial automatisms (e.g.: blinking eye) were present during the
postictal period. At 15 mg/kg of PB, the animals that were seizure-free
displayed similar behavior to that of the animals at 10 mg/kg of PB,
except for the strong presence of grooming behavior during the post-
stimulus period. Differenceswere noted in the animals that had seizures;
they only presented wild running behavior itemswith high interactions,
and therewas an exploratory cluster of low frequency and duration dur-
ing the stimulus window. At 20 mg/kg doses, all the animals were
seizure-free in all of the observationwindows, with the principal behav-
ioral cluster being exploratory with a high frequency of all the items.
There was a high number of grooming behaviors at this dose. The cIS
and the AI showed signiﬁcant differences at all the doses in contrast to
the vehicle (Fig. 6).The neuroethological sequence (Fig. 7) of the hamsters injectedwith
VPA showed a clear-cut effect of the doses that had an anticonvulsant
effect and those that did not. At a lower dose, 100 mg/kg, all the animals
had seizures, and no differences were seen in the prestimulus window.
When the stimulus began, some exploratory items accompanied the
wild running behavior, which decreased the interactions between the
different behaviors in the cluster. During the postictal immobility win-
dow, orofacial automatisms, such as eye-blinking and mastication,
were observed. At 150 mg/kg dose of VPA, some ataxic walkingwas ob-
served, and there was an increase in the interactions between the ex-
ploratory items in the stimulus window. After the exploration cluster,
wild running was initiated and was followed by the regular phases of
the seizure pattern. Additionally, automatisms were still present in
the postictal phase, and some ataxia was noted at this point. At
300 mg/kg VPA, 66.6% of the animals lacked seizures, the exploratory
cluster decreased, and the interactionswere lower in all threewindows.
Once the sound stopped, freezing behavior was observed, followed by
exploration. The level of ataxia at this point was highly pronounced
(Fig. 8). At a higher dose, 500 mg/kg VPA, no animal had seizures, and
themain behavioral clusterwas exploratory. Somewild running behav-
iors were present but were not maintained as in the previous dose.
The frequency and duration of the exploratory behavior were lower
than normal, except for during the poststimulus window, when they
were accompanied by a marked ataxic walk (Fig. 8).
Fig. 7. Flowchart of the behavior of the GASH:Sal hamsters injected with different doses of VPA.
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Fig. 8. Box plots showing: A) the categorized seizure severity (cSI) and B) the ataxic
index (AI) at the different doses of VPA.
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seizures. As shown in Fig. 9, the exploration clusters were affected in
all three windows (lower frequency and duration), and interactions
between the items were highly decreased when compared with the
control group. As seen with the other AEDs, in the animals that had sei-
zures, there was an increase in the latency to wild running. At a LEV
dose of 50 mg/kg, 50% of the animals lacked seizures, and there was
an increase in the interactions between the exploratory behaviors.
Some grooming items were seen during the poststimulus window. At
80-mg/kg dose, 66% of the animals had complete seizures, but there
was an increase in the latency period to wild running, and orofacial
automatisms were present. At the ﬁnal dose (100 mg/kg), 66% of the
animals did not have seizures, and themain componentwas the explor-
atory cluster in all three windows. No other cluster had a signiﬁcant
presence in the ﬂowchart. In addition to the lack of an anticonvulsant
effect, LEV also produced high toxicity effects, such as ataxia and seda-
tion (Fig. 10).4. Discussion
Validation of the GASH:Sal hamster as a chronic model of general-
ized epilepsy may reveal the physiological and neurochemical changes
that manifest in the epileptic brain. The present study shows that theanticonvulsant effects of PB and VPA, both with a similar proﬁle, are
dose-dependent and that PB and VPA have higher anticonvulsant po-
tency than LEV in the GASH:Sal hamster seizure model. This result con-
tributes to our understanding of the effects of AEDs.
An animal model of epilepsy is validated when, in addition to being
able to reliably reproduce the objective symptoms and EEG features of
the epilepsy syndrome, it is also able to respond to targeted pharmaco-
logical treatment. As an additional strategy to increase our understand-
ing of the pathophysiology of epilepsy, the GASH:Sal hamster has been
observed to mimic generalized seizures [37] and to respond to treat-
ment. As such, the GASH:Sal hamster serves as a useful tool for the de-
sign and evaluation of new AEDs.
Animal models of disease serve an indispensable function in identi-
fying the biochemical basis of disease and aiding in the development of
biological screening methods for molecules with the potential to sup-
press or stop disease progression. Organisms such as worms, ﬂies,
yeast, or ﬁsh serve as a complementary approach to in vitro assays
and are employed in a wide variety of studies, ranging from develop-
mental and cellular processes to gene mapping and screening. One ad-
vantage of a rodent model is its repertoire of complex behaviors [38];
therefore, it has long been the standard choice for pharmaceutical
drug target validation. However, when choosing an appropriate model
for AED screening, special attention must be paid to the processes un-
derlying the epileptogenesis of a particular epilepsy syndrome. There
is an extensive discussion about which types of models are the best
for studying AEDs. The use of epilepsy models (e.g., Genetic Absence
Epilepsy Rat from Strasbourg) or seizure models (e.g., maximal electro-
shock seizure) depends on the focus of the study [12]. Lösher [39] sug-
gests that models resulting from spontaneous mutations, such as AS
models, are preferred for drug development. The complexity of the
epilepsies and the need for a better understanding of the mechanisms
underlying them are reﬂected in the ongoing characterization and en-
hancement of animal models [11,12,39,40].
When looking to the neuroethological evaluation of GASH:Sal of the
current study, we can see that in the prestimulus observation window,
the hamsters were hyperactive with high levels of exploratory behavior,
which is congruentwith the normal anxious behavior of the species [41].
When the behavioral sequence of the drug-free hamster group was ob-
served, it was noticed that, with slight variations, the seizure pattern
was quite standard. This is compatible with an already demonstrated
stable inherited mutation associated with the epileptogenic circuits in
the GASH:Sal inbred strain [36]. Nevertheless, the minimal differences
in latency and wild running were considered and explored, although
they did not show statistical signiﬁcance (data not shown), as if there
was a kindling component consequence of repeated stimulation. Al-
though this did not seem to be the case, the presence of kindling
would naturally affect our interpretation of the effects of the AEDs on
the behavioral sequences of the studied hamsters because all doses of a
given drug were applied to the same animal but with sufﬁcient time in-
tervals between doses.
Phenobarbital is one of the oldest AEDsused in the clinical treatment
of epilepsy and has been validated in different animal epilepsy models
[40]. Phenobarbital is rapidly and completely absorbed following i.p.
administration. Phenobarbital was the AED that had the highest range
of anticonvulsant effect, and it can block seizures in a dose-dependent
manner from 5 to 20 mg/kg. With a dose of 10 mg/kg, only 33.33% of
the animals seized, and they also showed a longer latency period,
most likely because of the protective action of the drug. When the ani-
mals ﬁnishedwild running, they continued to show exploratory behav-
ior. These data indicate that PB at lower doses protects by avoiding the
propagation of electric onset generated by the stimulus, possibly due to
blockade of the Na2+ and Ca2+ channels [34,42,43]. At higher doses,
PB fully blocks the seizure by enhancing the inhibition that is mediated
by longer opening of the GABA-A channels, thereby decreasing the hy-
peractivity of glutamate and dopamine [44]. By increasing the PB dose,
the animals' normal behavior (prestimulus window) was affected by
Fig. 9. Flowchart of the behaviors of the GASH:Sal hamsters injected with different doses of LEV.
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Fig. 10. Box plots of A) the categorized seizure severity (cSI), B) ataxic (AI), and C) se-
dation (SdI) indexes of the different doses of LEV.
423B. Barrera-Bailón et al. / Epilepsy & Behavior 28 (2013) 413–425the drug. Ataxic walking and falls, in conjunction with an increase in
grooming behavior, accompanied the exploration, except at the highest
dose (in which the hamsters had the highest level of ataxia).
In our study, which used a nonselective depressor of the nervous
central system, we observed high levels of ataxia, related to high
doses of PB, mainly 15 and 20 mg/kg, but similar to Silva Brum andElisabetsky [40], we did not observe any sedation, which is in contrast
to other rodentmodels [34,40,45–47]. The presence of groomingbehav-
ior associated with toxic doses of PB needs further study because this
behavior is extremely sensitive to pharmacological treatment and is
recognized as a reliable marker of stress-related disturbances and, in
some cases, is a useful model for studying the organization and neural
mechanisms of movement sequences [48,49].
Valproic acid, one of the oldest classical anticonvulsant drugs, acts
similarly to PB to enhance the inhibitory actions of GABA [29,43,44].
The administration of VPA causes an elevation of cerebral GABA levels
in rodents [50], which coincides with the period of protection against
ASs [51]. In contrast, other authors have demonstrated that VPA in-
duces anticonvulsant activity against AS and electroshock-induced
convulsions at doses that are insufﬁcient to raise brain GABA levels
[52–54]. Valproic acid blocks seizures induced by pentylenetetrazole
and maximal electroshock and shows antikindling properties [55] in
a variety of animal models. In our experimental conditions, the maxi-
mum plasmatic level was observed 15 min after intraperitoneal admin-
istration of the drug, which is in agreement with the results obtained in
other animals [56,57]. In our model, VPA only showed anticonvulsant
activity at the highest dose, 300 mg/kg, and was accompanied by high
levels of ataxia. We observed that animals with VPA at doses below
300 mg/kg maintained some wild running elements despite not seiz-
ing. Furthermore, the ataxic effect starts at 150 mg/kg, showing high
toxicity of this drug. At the same time, it produces not only anticonvul-
sant effects but also ataxic walking. According to some authors, VPA has
relatively low neurotoxicity in gerbils and rats, and, in mice, some
sedation is seen at doses necessary to block convulsions [31,58,59].
The neurotoxic manifestation at anticonvulsant doses could be related
to speciﬁc characteristics of the hamster species. There is extended in-
formation regarding the toxic effects of VPA in embryos, but there is a
lack of information on the behavioral effects caused by VPA, mainly be-
cause of the low neurotoxicity seen in human adults [58].
Levetiracetambelongs to a group of nootropic drugs called racetams
[60] that have anticonvulsant and neuroprotective properties [61] but
have failed to reveal a generally acceptedmechanism of action and usu-
ally show no afﬁnity for themajor receptors. Levetiracetam binds to the
SV2A vesicle receptor in the cortex and hippocampus, increasing GABA
[62] in addition to reducing the Ca2+ N type current [44,62,63]. In our
study, the effect of LEV was not clear at any of the doses; indeed, at all
doses, there were animals that presented seizures. Levetiracetam is
devoid of protective effects in acute seizuremodels [64] but exhibits an-
ticonvulsant activity in a dose-dependent manner in chronic treatment
AS animal models [65] and in kindling models [66]. Therefore, it would
be useful to observe the effects of LEV in a chronic condition model to
determine if LEV has anticonvulsant effects on the GASH:Sal strain.
Moreover, LEV was the only AED that induced sedation with ataxia,
which is not a surprising result as sedation and somnolence are com-
monly reported side effects for this AED [67,68].
To completely determine the antiepileptic effect of the AEDs stud-
ied in these experiments, all the neuroethological datamust be associ-
ated to electroencephalographic analysis. In the case of LEV, an EEG
study could help us understand the ﬂuctuating effect of the drug at dif-
ferent doses. This would help to determine if the GASH:Sal hamster
would be a goodmodel for developing drugswith similarmechanisms
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